The main objective of the Investment approach is to generate capital appreciation through investments in equities with a medium to long-term perspective.
| Alpha (1Y) | Beta (1Y) | Standard Deviation (1Y) | % of +ve Months (SI) |
|---|---|---|---|
| 18.23% | 0.48 | 11.71% | 60% |
Performance Table #
| Trailing Returns (%) | 1m return | 3m return | 6m return | 1y return | 2y return | 3y return | 5y return | 10y return | Since inception return |
|---|---|---|---|---|---|---|---|---|---|
| Kotak AMC Pharma Fund | -7.90% | -13.70% | -14.80% | 2.00% | 25.70% | 13.50% | 21.40% | - | 12.50% |
| NIFTY 50 TRI | -5.80% | -8.10% | -12.00% | 1.90% | 14.40% | 10.90% | 15.90% | - | 12.90% |
QRC Report Card *
| Strategy | Category | Fund Manager | Date of Inception | Age Of PMS | Corpus (in Cr, approx) | Benchmark | Returns SI (CAGR) | Stocks In Portfolio | Sectors In Portfolio |
|---|---|---|---|---|---|---|---|---|---|
| Kotak AMC Pharma Fund | Multi Cap | Anshul Saigal | 20 September 2016 | 8Y 5M | 24 | NIFTY 50 TRI | 12.50% | 14 | 19 |
| Portfolio Quality (Q) | Portfolio Risk (R) | Portfolio Consistency (C) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Index | Category Alpha (1Y) | Relative Alpha (1Y) |
% of +ve Months
(Fund Data) |
Alpha (1Y) | Beta (1Y) |
Standard Deviation (1Y)
(Fund Data) |
Sharpe Ratio (1Y)
(Fund Data) |
Alpha (SI) | Information Ratio (SI) | Consistency Ratio % |
| Nifty 50 | 12.70% | 11.89% | 60% | 24.59% | 0.48 | 11.71% | 2.53 | 2.25% | 0.14 | 51.00 % |
| Nifty 500 | 8.12% | 10.11% | 18.23% | 0.48 | 0.92% | 0.06 | 51.00 % | |||
| Nifty Midcap 100 | -1.03% | 10.57% | 9.54% | 0.45 | -1.95% | -0.11 | 48.00 % | |||
| Nifty Smallcap 100 | -0.75% | 10.2% | 9.45% | 0.23 | 0.77% | 0.04 | 47.00 % | |||
VIEW DETAILED QUALITY, RISK, CONSISTENCY ANALYSIS
Portfolio Holdings
| Holding | % |
|---|---|
| SUN PHARMACEUTICAL INDUSTRIES LTD | 16.46 |
| CIPLA LTD | 12.45 |
| FORTIS HEALTHCARE LTD | 7.63 |
| IPCA LABORATORIES LTD | 6.08 |
| DR REDDY'S LABORATORIES LTD | 6.08 |
| DIVI'S LABORATORIES LTD | 5.71 |
| ZYDUS LIFESCIENCES LTD | 5.62 |
| SYNGENE INTERNATIONAL LTD | 5.37 |
| TORRENT PHARMACEUTICALS LTD | 4.27 |
| LAURUS LABS LTD | 3.93 |
| AUROBINDO PHARMA LTD | 3.80 |
| BIOCON LTD | 3.56 |
| METROPOLIS HEALTHCARE LTD | 3.20 |
| HIKAL LTD | 3.18 |
| GLENMARK PHARMACEUTICALS LTD | 3.01 |
| GLAND PHARMA LTD | 2.99 |
| PIRAMAL PHARMA LTD | 2.72 |
| INDOCO REMEDIES LTD | 1.69 |
| AJANTA PHARMA LTD | 1.17 |
Sector Allocation
| Holding | % |
|---|---|
| PHARMA & BIOTECH | 5.62 |
| PHARMA & BIOTECH | 1.17 |
| PHARMA & BIOTECH | 16.46 |
| PHARMA & BIOTECH | 12.45 |
| HEALTHCARE SERVICES | 7.63 |
| PHARMA & BIOTECH | 2.99 |
| PHARMA & BIOTECH | 6.08 |
| HEALTHCARE SERVICES | 3.20 |
| PHARMA & BIOTECH | 5.71 |
| PHARMA & BIOTECH | 3.56 |
| HEALTHCARE SERVICES | 5.37 |
| PHARMA & BIOTECH | 3.80 |
| PHARMA & BIOTECH | 3.18 |
| PHARMA & BIOTECH | 6.08 |
| PHARMA & BIOTECH | 4.27 |
| PHARMA & BIOTECH | 1.69 |
| PHARMA & BIOTECH | 3.01 |
| PHARMA & BIOTECH | 3.93 |
| PHARMA & BIOTECH | 2.72 |
Market Cap Allocation
| Allocations | % |
|---|---|
| Large Cap | 52.10 |
| Mid Cap | 29.00 |
| Small Cap | 5.50 |
| Cash | 13.40 |
Do Not Simply Invest, Make Informed Decisions
WISH TO MAKE INFORMED INVESTMENTS FOR LONG TERM WEALTH CREATION
Book
a call with our PMS AIF Specialists
Disclaimer
#Returns as of 28 Feb 2025. Returns up to 1 Year are absolute, above 1 Year are CAGR.
*QRC Report Card data is updated quarterly. Current data is as of Dec 24.
